BioSpace News Archive

Formation Capital and Safanad Limited announce the sale of the parent company of RHA Health Services, LLC, the comprehensive provider of services to individuals with intellectual and developmental disabilities, behavioral health needs and substance use challenges to an affiliate of Blue Wolf Capital.

BTD is an FDA program designed to expedite the development and review of therapeutic candidates intended to treat serious or life-threatening diseases.

Add-on Payment Increased from 50 to 65 Percent; Supports Patient Access by Providing Additional Medicare Reimbursement in the Hospital Setting

ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases.

Mr. Sender brings over 30 years of financial leadership experience, with a strong track record of success.

Two key players in the OLED industry are collaborating to accelerate development of new products and for the advancement of OLED technology

Mr. Fleet has also been elected to serve as a member of the Company’s Board of Directors.

A global data analytics and advisory firm, Quantzig, that delivers actionable analytics solutions to resolve complex business problems has announced the completion of their latest customer segmentation analytics engagement for a pharmaceutical company.

The Company’s J-Plasma handpieces are indicated for cutting, coagulation and ablation of soft tissue during open and laparoscopic surgical procedures.

BTG plc (LSE: BTG), the global healthcare company, today announced the start of a randomized double-blinded clinical study, initiated by researchers at the University of Maryland School of Medicine (UMSOM), that examines the role of DigiFab® (Digoxin Immune FAB (ovine)) in patients with an elevated risk of acute kidney injury undergoing coronary artery bypass graft (CABG) surgery.